Anastasiia Neelagaru, MD
Geriatric Medicine · Albuquerque, NMNPI 1114284445
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 65.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $3,631 and has fallen 87.5% since, to $454 in 2025.
Across 86 payments — averaging $61.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$3K
- Novo Nordisk$408
- Boehringer Ingelheim$258
- Merck$170
- Novartis$155
- Abiomed$147
- plus $704 from 16 others
What the payments were for
- Speaking & faculty fees$3,13059%
- Travel & lodging$862%
- Food & beverage$2,09839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 8 | $3,473 |
| Novo Nordisk | 15 | $408 |
| Boehringer Ingelheim | 13 | $258 |
| Merck | 5 | $170 |
| Novartis | 7 | $155 |
| Abiomed | 4 | $147 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Lilly USA, LLC | 6 | $91 |
| Amgen | 4 | $86 |
| Pfizer | 4 | $79 |
| Bayer | 4 | $64 |
| Exact Sciences | 3 | $53 |
| GSK | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Exeltis, USA Inc. | 1 | $19 |
| AbbVie | 1 | $16 |
| Viiv Healthcare Company | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few geriatric medicine providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 94 | $126,493 |
| OzempicSemaglutide | 95 | $116,489 |
| EliquisApixaban | 89 | $89,540 |
| TrulicityDulaglutide | 53 | $69,266 |
| JanuviaSitagliptin Phosphate | 24 | $30,117 |
| MounjaroTirzepatide | 24 | $26,384 |
| Spiriva HandihalerTiotropium Bromide | 33 | $25,845 |
| MyrbetriqMirabegron | 20 | $16,017 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,560 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $7,752 |
| Levothyroxine Sodium | 549 | $7,498 |
| Atorvastatin Calcium | 433 | $6,779 |
| PremarinEstrogens, Conjugated | 14 | $5,877 |
| Fluticasone Propionate HfaFluticasone Propionate | 23 | $5,748 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $258 | $126,49394 claims |
| Novo NordiskOzempic | $408 | $116,48995 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $91 | $95,65077 claims |
| PfizerEliquis, Premarin | $79 | $95,417103 claims |
| MerckJanuvia | $170 | $30,11724 claims |
| Astellas Pharma US IncMyrbetriq | $3,473 | $16,01720 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $32 | $11,40022 claims |
| AbbVieSynthroid | $16 | $1,11422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other geriatric medicine in Albuquerque
- Janice KnoefelAlbuquerque$4K
- Kirsten SilveyAlbuquerque$256
- Nadia MarshAlbuquerque$119
- M LodhiAlbuquerque$107
- David ScraseAlbuquerque$20
- Alexander DeradkeAlbuquerque$20
- Andrea LillAlbuquerque$0
- Carla HermanAlbuquerque$0
- Sharon KnobelsdorfAlbuquerque$0
- Jesus DuranLas Cruces$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.